Dongwha Pharm.Co.,Ltd (KRX:000020)

Dongwha Pharm.Co.,Ltd Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	493,332	464,875	361,109	340,426	293,018	272,075
Other Revenue	0	-	-	-0	-	-
Revenue	493,332	464,875	361,109	340,426	293,018	272,075
Revenue Growth (YoY)	15.14%	28.73%	6.08%	16.18%	7.70%	-11.42%
Cost of Revenue	272,054	250,617	170,693	159,436	143,671	133,409
Gross Profit	221,277	214,258	190,416	180,990	149,347	138,666
Selling, General & Admin	175,983	165,146	142,338	125,515	103,217	92,288
Research & Development	23,313	23,599	21,548	19,285	17,338	16,912
Amortization of Goodwill & Intangibles	3,178	2,976	1,139	1,327	1,491	1,174
Other Operating Expenses	2,427	2,362	2,291	1,993	1,808	1,930
Operating Expenses	214,182	200,847	171,750	151,075	126,848	115,588
Operating Income	7,096	13,411	18,666	29,915	22,499	23,078
Interest Expense	-3,613	-2,152	-308.01	-370	-383.11	-292.15
Interest & Investment Income	2,021	2,491	6,683	2,493	1,744	1,840
Earnings From Equity Investments	0	-219.37	2,420	-2,269	-410.4	-114.11
Currency Exchange Gain (Loss)	-468.28	-460.25	377.78	31.87	687.36	-499.17
Other Non Operating Income (Expenses)	-143.25	566.8	145.65	527.55	630.9	-357.6
EBT Excluding Unusual Items	4,891	13,637	27,985	30,328	24,768	23,655
Gain (Loss) on Sale of Investments	-4,749	-6,435	9,434	-4,506	1,801	2,561
Gain (Loss) on Sale of Assets	9,024	21.1	28.76	741.89	169.46	7,462
Asset Writedown	-94.81	-321.16	-491.98	-3,478	-316.08	-39.91
Other Unusual Items	-	-	-	-	105.41	-
Pretax Income	9,071	6,902	36,956	23,086	26,527	33,638
Income Tax Expense	5,334	4,756	8,719	1,494	6,944	4,923
Earnings From Continuing Operations	3,737	2,146	28,237	21,591	19,583	28,715
Minority Interest in Earnings	3,855	3,417	-798.76	-1,208	-1,712	-207.41
Net Income	7,592	5,563	27,438	20,383	17,870	28,508
Net Income to Common	7,592	5,563	27,438	20,383	17,870	28,508
Net Income Growth	-1.05%	-79.72%	34.61%	14.06%	-37.31%	212.72%
Shares Outstanding (Basic)	28	28	28	28	28	28
Shares Outstanding (Diluted)	28	28	28	28	28	28
Shares Change (YoY)	0.15%	0.12%	0.02%	0.16%	0.05%	0.05%
EPS (Basic)	273.72	200.71	991.07	736.42	646.68	1032.60
EPS (Diluted)	273.72	200.71	991.07	736.42	646.68	1032.51
EPS Growth	-1.20%	-79.75%	34.58%	13.88%	-37.37%	212.88%
Free Cash Flow	-54,094	-40,689	4,626	10,792	14,087	17,982
Free Cash Flow Per Share	-1950.25	-1467.95	167.09	389.91	509.78	651.02
Dividend Per Share	180.000	180.000	180.000	180.000	180.000	180.000
Gross Margin	44.85%	46.09%	52.73%	53.17%	50.97%	50.97%
Operating Margin	1.44%	2.89%	5.17%	8.79%	7.68%	8.48%
Profit Margin	1.54%	1.20%	7.60%	5.99%	6.10%	10.48%
Free Cash Flow Margin	-10.96%	-8.75%	1.28%	3.17%	4.81%	6.61%
EBITDA	28,135	33,080	32,562	42,424	34,591	33,785
EBITDA Margin	5.70%	7.12%	9.02%	12.46%	11.80%	12.42%
D&A For EBITDA	21,040	19,669	13,896	12,509	12,093	10,707
EBIT	7,096	13,411	18,666	29,915	22,499	23,078
EBIT Margin	1.44%	2.89%	5.17%	8.79%	7.68%	8.48%
Effective Tax Rate	58.80%	68.91%	23.59%	6.47%	26.18%	14.64%
Advertising Expenses	-	48,368	41,140	34,455	29,889	27,532

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.